Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Pitolisant ...

Overworked businessman sitting in office, sleeping in front of laptop Obesity, night eating, parasomnia, sleep talking and drunkenness, and ADHD symptoms are more frequent in children than adults at ...

Please provide your email address to receive an email when new articles are posted on . A 14-item self-reported scale improved the management of and provided guidance for narcolepsy type 1 among ...

Children with narcolepsy often have disrupted nighttime sleep (DNS), which could lead to other effects, such as memory issues. Narcolepsy in children has a distinct association with disrupted ...

Please provide your email address to receive an email when new articles are posted on . Pitolisant 5 mg to 40 mg a day improved symptoms of narcolepsy in children aged 6 to 17 years. Safety profile ...

The US Food and Drug Administration (FDA) has approved Avadel Pharmaceuticals’ supplemental new drug application for extended-release sodium oxybate (Lumryz) for treatment of cataplexy or excessive ...

Narcolepsy type 1 (NT1) may be caused by an autoimmune T-cell response to orexins and could be triggered by flu antigens, according to study findings. Narcolepsy type 1 (NT1) may be caused by an ...

Narcolepsy was linked to high blood pressure, hyperlipidemia, and diabetes on top of outright cardiovascular disease events in a retrospective cohort study. Notably, patients with narcolepsy started ...

Lois E. Krahn, MD, professor of psychiatry, Mayo Clinic College of Medicine; sleep specialist, Mayo Clinic, Scottsdale, AZ. I've been doing narcolepsy work for 25 years, and there has never been a ...

She is only 14, but at times she has wondered if her life is worth living. Emelie is one of around 800 children in Sweden and elsewhere in Europe who developed narcolepsy, an incurable sleep disorder, ...

DUBLIN, April 24, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line efficacy results from the global, double-blind, placebo-controlled, ...